CHA Biotech wins government backing to advance cell and gene therapy platform
CHA Biotech has secured government backing for a three-and-a-half-year research project aimed at pushing its cell and gene therapy platforms toward clinical development, with 31.5 billion won ($22.7 million) in funding. The biotechnology company said Tuesday that it was selected for a follow-up research and development project under the 2026 K-HERO Development and Support Program, led by the…
CHA Biotech has secured government support for a three-and-a-half year research endeavor, receiving 31.5 billion won ($22.7 million) in funding. The biotech firm was chosen for a follow-up research project under the 2026 K-HERO Development and Support Program, managed by the Ministry of Science and ICT and the Korea Industrial Technology Association.
The initiative backs corporate research centers working on national strategic technologies, aiming to develop core technologies and transform them into market-ready products. CHA Biotech will allocate the funds to develop and commercialize two platforms, CHAMS, a standardized source-cell platform derived from mesenchymal stem cells, and CHAGE, which employs therapeutic genes to augment cell function.
The company intends to integrate these platforms into a comprehensive development system applicable to a wide array of challenging diseases, rather than focusing on a single ailment.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
